TRAIN-HEART Network
The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
People
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
Research Programme
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
Contact
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
TRAIN-HEART scientists at Maastricht University and Hannover Medical School joined published an key review article on non-coding RNAs in cardiac inflammation, also described as key drivers in the pathophysiology of heart failure.
Fri, 10 February
The TRAIN-HEART network had such a fantastic network meeting in Milan. Excellent scientific talks, and exciting cultural activities. Thanks to all the participants and who made this happen
Wed, 04 January
During previous TRAIN-HEART network meeting in Milan (28-30 September 2022), the winners of the business case and elevator pitch competition were announced: EASY-COR. The work package 1 team prepared the best business case and presentation pitch and won a 250€ travel/conference award for each team member. An independent refereee panel reviewed all cases and pitches and the end-result was very tight.
Wed, 23 November
In Berlin this summer several TRAIN-HEART fellows presented their work at the International Society for Heart Research (ISHR) World Congress 2022. The spirit of ISHR is characterized by the scientific and social interactions of their members, and we can not agree more with this.
Thu, 08 September
For years, Professor Dr. Dr. Thomas Thum, head of the Institute for Molecular and Translational Therapy Strategies at the Hannover Medical School (MHH) and institute director of Fraunhofer ITEM, has been researching a remedy for the hitherto incurable cardiac fibrosis. He has already received the highest science funding from the European Union for this, an European Research Council (ERC) Advanced Grant.
Tue, 21 June
